Tweet
Hum Vaccin Immunother. 2019 Jun 18. doi: 10.1080/21645515.2019.1633877. [Epub ahead of print]
Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine.
Bianchini S1, Orabona C2, Camilloni B3, Berioli MG1, Argentiero A1, Matino D2, Alunno A3, Albini E2, Vacca C2, Pallotta MT2, Mancini G1, Tascini G1, Toni G1, Mondanelli G2, Silvestri E1, Grohmann U2, Esposito S1.
Author information
Abstract
This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.
KEYWORDS:
GG; : influenza; influenza vaccine; probiotic; proinflammatory cytokines; type 1 diabetes (T1D)
PMID: 31210557 DOI: 10.1080/21645515.2019.1633877
Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine.
Bianchini S1, Orabona C2, Camilloni B3, Berioli MG1, Argentiero A1, Matino D2, Alunno A3, Albini E2, Vacca C2, Pallotta MT2, Mancini G1, Tascini G1, Toni G1, Mondanelli G2, Silvestri E1, Grohmann U2, Esposito S1.
Author information
Abstract
This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.
KEYWORDS:
GG; : influenza; influenza vaccine; probiotic; proinflammatory cytokines; type 1 diabetes (T1D)
PMID: 31210557 DOI: 10.1080/21645515.2019.1633877